— Know what they know.
Not Investment Advice

ABCL

AbCellera Biologics Inc.
1W: -3.7% 1M: +5.3% 3M: -8.9% YTD: -1.2% 1Y: +30.9% 3Y: -55.2% 5Y: -89.2%
$3.39
+0.08 (+2.42%)
After Hours: $3.42 (+0.03, +1.03%)
NASDAQ · Healthcare · Biotechnology · $1.0B · Alpha Radar Neutral · Power 52
Smart Money Score
Moderate 50
Insider+$15.4M
Congress
ETF Holdings
Key Statistics
Market Cap$1.0B
52W Range1.891-6.515
Volume1,663,008
Avg Volume4,130,832
Beta0.87
Dividend
Analyst Ratings
9 Buy 2 Hold 0 Sell
Consensus Buy
Company Info
CEOCarl Hansen
Employees596
SectorHealthcare
IndustryBiotechnology
IPO Date2020-12-11
2215 Yukon Street
Vancouver, BC V5Y 0A1
CA
604 559 9005
About AbCellera Biologics Inc.

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Recent Insider Trades

NameTypeSharesPriceDate
Thermopylae Holdings P-Purchase 38,000 $3.44 2026-02-27
Booth Andrew P-Purchase 42,600 $3.42 2026-02-27
Thermopylae Holdings P-Purchase 177,457 $3.27 2026-02-26
Booth Andrew A-Award 808,898 $3.42 2026-01-01
Hansen Carl L. G. A-Award 2,106,505 $3.42 2026-01-01

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms